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The use of chemotherapy is considered standard therapy in patients with locally advanced non-small-cell lung cancer that
cannot be treated with radiotherapy and in those with metastatic non-small-cell lung cancer and good performance status.
This approach is also accepted in patients with earlier stage disease, when combined with radiotherapy in those with non-
resectable locally advanced disease, or in the preoperative setting. Randomised clinical studies and meta-analyses of the
literature have conﬁrmed the beneﬁcial survival effect of platinum-based chemotherapy. Cisplatin and carboplatin have been
successfully used with other drugs in a wide variety of well-established two-drug combinations while three-drug combinations
are still under investigation. Cisplatin and carboplatin use is limited by toxicity and inherent resistance. These considerations
have prompted research into new platinum agents, such as the trinuclear platinum agent BBR3464, the platinum complex
ZD0473 and oxaliplatin. These compounds could be developed in combination with agents such as paclitaxel, gemcitabine or
vinorelbine in patients with advanced and/or refractory solid tumours.
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Lung cancer has the highest mortality rate of any major malig-
nancy in the developed world, causing an estimated 1 million
deaths worldwide annually (Abratt, 1995). In the United States
alone it has been estimated that 157400 deaths from lung cancer
will occur in 2001 (American Cancer Society (http://www.cancer.
org/ (accessed 18 September 2001)). Mortality due to lung cancer
exceeds that related to breast, prostate, colorectal and ovarian
cancers combined (American Cancer Society, 2001). Approximately
85–90% of cases of lung cancer are attributable to smoking (Bunn
et al, 1998).
Non-small-cell lung cancer (NSCLC) represents approximately
75–80% of all lung cancer (Abratt, 1995; Bunn et al, 1998; Natale,
1998). Fewer than 25% of patients have resectable disease, due to
locally advanced or metastatic disease, which does not allow surgery
despite improvements in diagnosis and peri- and postoperative care
(Bulzebruck et al, 1992). Also, comorbidities, mostly linked to
tobacco, may prevent patients with potentially resectable disease
from receiving surgery. Overall 5-year survival is between 5 and
13%, and varies with the different stages of the disease (Johnson,
1995; Mountain, 1997; Natale, 1998; Breathnach et al, 2001).
This review outlines current treatment options for patients with
NSCLC with emphasis on the use of platinum-containing regi-
mens. This disease is inherently resistant to chemotherapy and is
associated with lower response rates than many other malignancies
(Bunn et al, 1998; Natale, 1998) and the optimal treatment is yet to
be determined (Breathnach et al, 2001).
MANAGEMENT OF NSCLC
Surgery or radiotherapy is the standard option for patients with
early stages of NSCLC. Chemotherapy has shown beneﬁt when
used alone in patients with stage IV disease, in combination with
radiotherapy in patients with locally advanced disease and in the
preoperative setting in those with early stages of NSCLC.
Surgery and primary radiotherapy
Surgery provides the best chance for cure of localised disease. It is
therefore the treatment of choice in stages 0, I and II NSCLC
(Deslauriers and Gregoire, 2000). With very careful patient selec-
tion, surgery may also be used as part of combined modality
treatment in stages IIIA and IIIB (T4) disease (Rosell et al, 1994;
Roth et al, 1994; CancerLinksUSA, http://www.cancer101.net
(accessed May 26, 2001)) or stage IV disease to remove single
metastatic lesions. However, even if surgery is the best treatment
possible, the results are still unsatisfactory with a 5-year survival
of less than 35%. These results have led clinicians to evaluate
combined modalities of treatment including chemotherapy.
Primary radiotherapy (with curative intent) can be considered in
patients with inoperable stages I or II of the disease and sufﬁcient
pulmonary reserve. Analysis of one randomised and 26 nonrando-
mised studies in more than 2000 patients receiving radical
radiotherapy for stage I or II disease found that 5-year survival
rates ranged from 0 to 42% (Rowell and Williams, 2001). Primary
radiotherapy used to be the ‘gold standard’ treatment in locally
advanced NSCLC.
Chemotherapy
The poor efﬁcacy and considerable toxicity of chemotherapy
caused great pessimism for many years regarding this approach,
as only a small impact on survival was observed.
During the 1980s, cisplatin and carboplatin were studied exten-
sively in NCSLC (Bunn, 1989a,b). Randomised trials as well as
meta-analyses provided scientiﬁc evidence that platinum-based
therapy prolonged survival of patients with advanced NSCLC Received 8 February 2002; revised 4 July 2002; accepted 23 July 2002
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nal NSCLC (non resectable stages IIIA and IIIB disease) (Non-
Small Cell Lung Cancer Collaborative Group, 1995). Experience
over the past two decades has shown improvements in survival,
symptom control and quality of life in patients with NSCLC who
receive chemotherapy instead of best supportive care, and
chemotherapy is now considered standard treatment in individuals
with advanced NSCLC (Splinter, 1990; Non-Small Cell Lung
Cancer Collaborative Group, 1995; Bunn and Kelly, 1998; Johnson,
2000; Bahl and Falk, 2001). More recently, platinum-based
chemotherapy has shown to be of interest in the neoadjuvant
setting, before surgery in patients with resectable stage IIIA (Rosell
et al, 1994; Roth et al, 1998) and stages I to II disease (Depierre et
al, 2002). Combined therapy with a platinum and taxane before
surgery has also shown notable results, with a 1-year survival rate
of 85% in patients with stages I to IIIa NCSLC reported after treat-
ment with paclitaxel and carboplatin (Pisters et al, 2000). Another
large randomised Intergroup trial is ongoing in the United States
that is evaluating the efﬁcacy of paclitaxel plus carboplatin in
patients with early stage NSCLC.
The ﬁrst generation agents in NSCLC (cisplatin, mitomycin-C,
iphosphamide/cyclophosphamide, vindesine, vinblastine and etopo-
side) produced response rates ranging from 15 to 25% when used
as monotherapy (Bakowski and Crouch, 1983; Grant and Kris,
1995) but, with the exception of cisplatin, had an unclear effect
on survival. Second generation agents (gemcitabine, paclitaxel,
docetaxel, vinorelbine, irinotecan and topotecan) showed response
rates of 20–25% (Bunn et al, 1998). Moreover, randomised studies
comparing monochemotherapy with paclitaxel, gemcitabine or
docetaxel versus best supportive care showed a survival beneﬁt in
the chemotherapy arm, (Anderson et al, 2000; Ranson et al,
2000; Roszkowski et al, 2000) emphasising the results of the
meta-analysis of the NSCLCCOG (Non-Small Cell Lung Cancer
Collaborative Group, 1995). Additional reports of large randomised
trials (one a pooled analysis of two trials), each conducted in more
than 700 patients, have conﬁrmed the survival beneﬁt of cisplatin-
based combined two- or three-agent chemotherapy versus best
supportive care (Cullen et al, 1999; Stephens et al, 2002).
Cisplatin and carboplatin
Platinum agents have currently shown the greatest promise in
patients with NSCLC. These agents induce their cytotoxic effects
by targeting cellular DNA and are active against a number of
tumour types (Go and Adjei, 1999). Cisplatin is thought to act
by activating apoptosis and altering a number of other cellular
parameters. It forms adducts with all DNA bases but preferentially
binds to the N
7 positions of guanine and adenine in intact DNA.
The main DNA lesions produced by both cisplatin and carboplatin,
accounting for a total of 95% of platinum-DNA adducts, are at the
G-G, A-G and G-X-G intrastrand crosslinks (Fink and Howell,
2000).
The dosages at which these agents are given varies according to
the agent(s) with which they are being combined and the status of
the patient. However, cisplatin is usually given at a dosage of 50–
120 mg m
72 per cycle, whereas the dose of carboplatin is usually
customised for each patient using the area under the concentra-
tion-time curve (AUC) and renal function of the patient (Calvert
et al, 1989; Chatelut et al, 1995), because this drug undergoes
extensive renal excretion. An AUC of 4–6 per cycle, which is
approximately equivalent to a dose in the range 200–
350 mg m
72 per cycle, is usual. Both platinum agents are usually
given every 3–4 weeks, according to the haematological status of
the patient, for 3–6 cycles.
Analysis of the Southwest Oncology Group (SWOG) database of
2531 patients with extensive NSCLC (1974–1988) showed the use
of cisplatin to be an independent predictor of improved outcome
(Albain et al, 1991). Thus, most clinical studies of chemotherapy
in advanced or locoregionally advanced NSCLC in recent years
have incorporated cisplatin. However, because of the toxicity of
cisplatin (see below), less toxic platinum alternatives have been
developed. The most extensively evaluated has been carboplatin
(Bunn, 1989b), with studies demonstrating the efﬁcacy of carbopla-
tin, alone (Bonomi et al, 1989; Bunn, 1989a,b; Gatzemeier et al,
1990a; Kreisman et al, 1990) or in combination (Gatzemeier et
al, 1990b). The available data suggest that carboplatin can substi-
tute cisplatin in patients with stage IIIB/IV NSCLC (Lokich and
Anderson, 1998; Go and Adjei, 1999; Zatloukal et al, 2001).
However, direct comparisons between cisplatin- and carboplatin-
based chemotherapy have been very rare (Klastersky et al, 1990;
Gatzemeier et al, 1999). Rodriguez et al (2001) presented the
results of a randomised study comparing docetaxel plus cisplatin
or carboplatin versus vinorelbine plus cisplatin at the 2001 meeting
of the American Society of Clinical Oncology. Although the study
was not designed to compare carboplatin with cisplatin, results in
the carboplatin arm were inferior.
Two drug combinations Two types of trials have been conducted
to compare monochemotherapy with cisplatin-containing two agent
chemotherapy: comparisons with cisplatin monotherapy and
comparisons using monotherapy with the non-platinum agent.
The relative beneﬁts of combination therapy over monotherapy,
shown in many publications, resulted in combination therapy
becoming recognised standard practice (Splinter, 1990; Marino et
al, 1995; Lilenbaum et al, 1998) and a number of phase III studies
are currently underway or completed that investigate the relative
efﬁcacies of several new platinum-containing two-agent combina-
tion regimens (Table 1) (Kelly et al, 2001; Rodriguez et al, 2001;
Scagliotti et al, 2001; van Meerbeeck et al, 2001; Schiller et al, 2002).
Of note, Schiller et al (2002) compared cisplatin plus paclitaxel
(the ECOG standard of care) with the new combination regimens
of cisplatin plus gemcitabine or docetaxel and paclitaxel plus
carboplatin (four-arm study). No major differences were observed
in terms of efﬁcacy (objective response rate and survival) or toxi-
city. Similar ﬁndings were reported in a trial comparing paclitaxel
plus carboplatin with vinorelbine plus cisplatin (Kelly et al, 2001).
Comparisons between cisplatin containing double therapy and
monotherapy with the non-platinum agent Results of trials
comparing monotherapy with vindesine (Elliott et al, 1984;
Einhorn et al, 1986), etoposide (Rosso et al, 1990), teniposide
(Splinter et al, 1996), and vinorelbine (Depierre et al, 1994; Le
Chevalier et al, 1994) with the respective agent combined with
cisplatin showed consistently higher response rates in the combina-
tion therapy arm, but only about half showed a survival beneﬁt for
the combination (Table 2). Similarly, preliminary analysis of a
multicenter phase III trial comparing docetaxel vs docetaxel plus
cisplatin in patients with inoperable advanced and metastatic
NSCLC showed no survival advantage but a signiﬁcant improve-
ment in objective response rate with combination therapy
(Georgoulias et al, 2002; Table 2).
Comparisons between cisplatin containing double therapy and
cisplatin monotherapy Comparisons of cisplatin monotherapy
and combination therapy with cisplatin plus vindesine (Kawahara
et al, 1991), etoposide (Klastersky et al, 1989; Crino et al, 1990),
vinorelbine (Wozniak et al, 1998), paclitaxel (Gatzemeier et al,
2000), gemcitabine (Sandler et al, 2000) and tirapazamine (von
Pawel et al, 2000) consistently showed a higher response rate in
the combination therapy arm, but again only half of the trials showed
a survival beneﬁt for the combination therapy arm (Table 3).
Comparisons between carboplatin containing double therapy
and monotherapy with the non-platinum agent A comparison
between monotherapy with paclitaxel and paclitaxel plus carbopla-
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advantage in terms of objective response rate (16 vs 30%,
P50.0001) and survival distribution (6.5 vs 8.5 months,
P=0.023) in favour of combination therapy but no signiﬁcant
difference between treatments in 1-year survival rate (31 vs 36%)
(Lilenbaum et al, 2002). Similarly, a comparison of gemcitabine
with gemcitabine plus carboplatin in 275 patients with advanced
NSCLC showed higher objective response rates (12 vs 30%) and
a signiﬁcantly longer time to progression (4 vs 6 months,
P=0.001) with combination therapy; the median survival was 9
months for the whole study population (Sederholm, 2002).
Conclusions The survival results reported to date suggest that
the importance of inclusion of a platinum agent in the combina-
tion therapy setting is still at least open for discussion, although
it appears to be accepted that two-agent combination therapy is
better than monotherapy.
Three drug combinations No statistically signiﬁcant survival
difference has been observed between regimens containing cisplatin
in combination with doxorubicin and cyclophosphamide (CAP),
doxorubicin and 5-ﬂuorouracil (AFP), cyclophosphamide and
bleomycin (CBP), vindesine (VP), etoposide (EP), or vindesine
and mitomycin-C (MVP). Median survival ranged from 21.6 to
26.6 weeks. The MVP regimen showed a trend towards a higher
response rate than the other regimens in certain trials with no
beneﬁt on survival (Ruckdeschel et al, 1985). MVP showed super-
iority to EP in another trial (Ginopoulos et al, 1997). A recent trial
that compared triple therapy with cisplatin plus ifosfamide plus
mitomycin (MIP) with gemcitabine plus cisplatin showed a higher
response rate in the ‘modern’ double therapy regimen and no
difference in survival between the two arms (Crino et al, 1999).
Other comparisons between double and triple therapy with
modern drugs did not show any advantage for triple therapy over
double therapy (Alberola et al, 2001; Souquet et al, 2001).
Table 1 Recent phase III studies comparing platinum-based two agent combination therapies for patients with stage IIIb or IV NSCLC
Trial Platinum Additional agent Frequency
Schiller et al (2000) Cisplatin 75 mg m
72 d2 Paclitaxel 135 mg m
72 d1 Every 21 days
Cisplatin 100 mg m
72 d1 Gemcitabine 1000 mg m
72 d1, d8, d15 Every 28 days
Cisplatin 75 mg m
72 d1 Docetaxel 75 mg m
72 d1 Every 21 days
Carboplatin AUC 6 d1 Paclitaxel 225 mg m
72 d1 Every 21 days
Kelly et al (2001) Cisplatin 100 mg m
72 d2 Vinorelbine 25 mg m
72 week
71 Every 28 days
Carboplatin AUC 6 d1 Paclitaxel 225 mg m
72 d1 Every 21 days
Rodriguez et al (2001) Cisplatin 75 mg m
72 d1 Docetaxel 75 mg m
72 d1 Every 21 days
Carboplatin AUC 6 d1 Docetaxel 75 mg m
72 d1 Every 21 days
Cisplatin 100 mg m
72 d1 Vinorelbine 25 mg m
72 d1, d7, d14, d21 Every 28 days
Scagliotti et al (2001) Cisplatin 75 mg m
72 d2 Gemcitabine 1250 mg m
72 d1, d8 Every 21 days
Carboplatin AUC 6 d1 Paclitaxel 225 mg m
72 d1 Every 21 days
Cisplatin 100 mg m
72 d1 Vinorelbine 25 mg m
72 d1, d7, d14, d2162 then d1, d14 Every 28 days
Van Meerbeeck et al (2001) Cisplatin 80 mg m
72 d1 Paclitaxel 175 mg m
72 d1 Every 21 days
Cisplatin 80 mg m
72 d1 Gemcitabine 1250 mg m
72 d1, d8 Every 21 days
Paclitaxel 175 mg m
72 d1+gemcitabine 1250 mg m
72 d1, d8 Every 21 days
Table 2 Comparisons between cisplatin containing double therapy and monotherapy with the second agent in patients with advanced NSCLC
Study Patients enrolled Drugs Overall response rate (%) Median survival
Georgoulias et al (2002) 279 Docetaxel 100 mg m
72 d163 weeks 18 10 months
Cisplatin 80 mg m
72 d2+docetaxel 35
a 13 months
100 mg m
72 d163 weeks
Splinter et al (1996) 225 Teniposide 120 mg m
72 d1, d3, d5 6 5.9 months
or 360 mg m
72 d1
Cisplatin 80 mg m
72 d1+teniposide 22
a 7.2 months
120 mg m
72 d1, d3, d5 or 360 mg m
72 d1
Depierre et al (1994) 231 Vinorelbine 30 mg m
72 week
71 16 32 weeks
Cisplatin 80 mg m
7263 weeks+ 43
a 33 weeks
vinorelbine 30 mg m
72 week
71
Le Chevalier et al (1994) 612 Vinorelbine 30 mg m
72 week
71 14 31 weeks
Cisplatin 120 mg m
72 d1 and 29, then 30 40 weeks
every 6 weeks+vinorelbine 30 mg m
72 week
71
Cisplatin 120 mg m
72 d1 and d29, then 19 32 weeks
every 6 weeks+vindesine
3m gm
72 week
7166 weeks then every other week
Rosso et al (1990) 216 Etoposide 120 mg m
72 d1–3 7 6 months
Cisplatinm 60 mg m
72 d1–2+etopside 25.8
a 8 months
20 mg m
72 d1–3
Einhorn et al (1986) 124 Vindesine 14 18 weeks
Cisplatin 120 mg m
72+vindesine 27 26 weeks
Cisplatin 60 mg m
72+vindesine+ 20 17 weeks
mitomycin C
Elliott et al (1984) 105 Vindesine 7 4 months
Cisplatin+vindesine 33 11 months
a
aStatistically signiﬁcant difference relative to monotherapy.
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Three small studies are underway to assess combinations of oxali-
platin and gemcitabine (Franciosi et al, 2001), paclitaxel (Hoffman
et al, 2001) or vinorelbine (Monnet et al, 2002) in patients with
advanced NSCLC. Early results in 24 previously untreated (Hoff-
man et al, 2001), 28 previously untreated (Monnet et al, 2002)
and 10 previously treated (Franciosi et al, 2001) patients show
response rates of 25, 35 and 30%, respectively. Oxaliplatin mono-
therapy has also demonstrated activity in a small study of 33
patients with poor-prognosis NSCLC (Monnet et al, 1998).
Other chemotherapy options
In addition, combinations of paclitaxel or docetaxel with nonplati-
num agents such as gemcitabine have shown promising results
(Douillard et al, 2001b; Georgoulias et al, 2001). Indeed, such
combinations may be an option for patients unable to tolerate
platinum agents or those with compromised performance status.
In addition, patients with a performance status of 2 do not beneﬁt
from platinum-based chemotherapy (Soria et al, 2001). In general,
studies comparing non-platinum regimens with platinum-based
regimens are still ongoing. In one that is published (Georgoulias
et al, 2001), no signiﬁcant difference was seen between gemcitabine
plus docetaxel and cisplatin plus docetaxel. The results of such
trials need to be conﬁrmed.
Several of the newer agents have been studied as second line
chemotherapy in patients with NSCLC and have shown some efﬁ-
cacy (Socinski and Langer, 1999; Huisman et al, 2000; Miller and
Kris, 2000), especially docetaxel for which there has been two
randomised studies (Fossella, 1999a,b; Shepherd et al, 2000).
Combined modality and adjuvant therapy
The use of platinum-based chemotherapy in conjunction with
radiotherapy in patients with locally advanced unresectable
NSCLC has become standard since the studies of Le Chevalier
et al (1991) and Dillman et al (1990). The NSCLCCG meta-analy-
sis conﬁrmed the survival beneﬁt provided by giving cisplatin-
based chemotherapy before radiotherapy over radiotherapy alone
(Non-Small Cell Lung Cancer Collaborative Group, 1995).
Although it is standard to use induction chemotherapy followed
by radiotherapy, there are some arguments favouring concurrent
chemoradiation using chemotherapy at systemic dosages (Eber-
hardt et al, 1998; Jeremic et al, 1999) or at radiosensitising
dosages (Trovo et al, 1992; Schaake-Koning et al, 1994; Bardet
et al, 1997; Clamon et al, 1999). These two different treatment
modalities have been studied in a number of promising phase II
trials but there are very limited data from positive randomised
phase III trials (Schaake-Koning et al, 1994; Furuse et al, 1999).
Results of these phase III studies support the use of concurrent
chemotherapy and radiotherapy in preference to radiotherapy
alone (Schaake-Koning et al, 1994) or sequential chemotherapy
then radiotherapy (Furuse et al, 1999).
Problems with currently used platinum drugs
Toxicity Severe adverse effects limit the use of cisplatin (McKe-
age, 1995). Nephrotoxicity may be reduced but not suppressed by
hyper-hydration (Hamilton et al, 1989; Bissett et al, 1990).
However, this hyper-hydration is not possible in patients with
congestive heart failure, a condition that is not rare in patients
with NSCLC. Cisplatin is also one of the most emetogenic drugs
used, with considerable variability between individuals. Systematic
use of serotonin antagonists has improved control of acute emesis
but not delayed emesis (Fauser et al, 1999; Gralla et al, 1999).
Anemia can also occur during treatment with cisplatin. This can
be due to several mechanisms, including depletion of intrinsic
erythropoietin production (caused by peritubular renal cell deple-
tion), reduced bone marrow stem cell activity and the absence of
the stem cell reaction of administered erythropoietin (Dufour et
al, 1990; Canpolat et al, 1994; Wood and Hrushesky, 1995).
Nephrotoxicity and neurotoxicity have been considerably
reduced by replacing cisplatin with carboplatin, which shows
nephrotoxicity only when used in high dosages. Carboplatin,
however, causes dose-limiting myelosuppression (McKeage, 1995;
Table 3 Comparisons between cisplatin containing double therapy and cisplatin monotherapy in patients with advanced NSCLC
Study Patients enrolled Drugs Overall response rate (%) Median survival
Gatzemeier et al (2000) 414 Cisplatin 100 mg m
7263 weeks 17 8.6 months
Cisplatin 80 mg m
7263 weeks+ 26
a 8.1 months
paclitaxel 175 mg m
7263 weeks
Sandler et al (2000) 522 Cisplatin 100 mg m
72 d164 weeks 11 7.6 months
Cisplatin 100 mg m
72 d164 weeks+ 30
a 9.1 months
a
gemcitabine 1000 mg m
72 d1, d8 and d1564 weeks
von Pawel et al (2000) 437 Cisplatin 75 mg m
7263 weeks 14 27.7 weeks
Cisplatin 75 mg m
726+tirapazamine 28
a 34.6 weeks
a
390 mg m
7263 weeks
Wozniak et al (1998) 415 Cisplatin 100 mg m
7264 weeks 12 6 months
Cisplatin 100 mg m
7264 weeks 26
a 8 months
a
vinorelbine 25 mg m
72 week
71
Kawahara et al (1991) 160 Cisplatin 80 mg m
72 d1 12 39 months
Cisplatin 80 mg m
72 d1+vindesine 29
a 45 weeks
3m gm
72 d1, d8, d15
Crino et al (1990) 156 Cisplatin 120 mg m
7263 weeks 4 18 weeks
Cisplatin 120 mg m
72+etoposide 30 35 weeks
a
100 mg m
72 d1–363 weeks
Cisplatin 120 mg m
72+etopside 26 37 weeks
a
100 mg m
72 d1–363 weeks+
mitomycin-C 10 mg m
72 d1, d21, d42, then 6-weekly
Klastersky et al (1989) 162 Cisplatin 120 mg m
72 d1 19 26 weeks
Cisplatin 120 mg m
72 d1+etoposide 26 22 weeks
100 mg m
72 d1–3
aStatistically signiﬁcant difference relative to monotherapy.
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ubin levels have also been observed (Fields et al, 1995).
Resistance Kelland (2000) and Giaccone (2000) reviewed
recently in detail the inherent resistance of NSCLC to current plati-
nums. NCSLC is inherently resistant to treatment with cisplatin
(Giaccone, 2000), so an understanding of the mechanisms behind
this could help to improve the prognosis of many patients with
the cancer. Thus, resistance to cisplatin has been studied exten-
sively in vitro. A number of resistance mechanisms have been
identiﬁed including: (a) increased repair of platinum-induced
DNA damage (increased nucleotide excision repair or loss of
DNA mismatch repair); (b) glutathione or metallothionein drug
deactivation; (c) reduced cellular uptake of the platinum; (d)
altered apoptosis (Kelland, 2000).
The clinical relevance of these mechanisms is currently not
entirely clear; however, tumour cell overexpression of metallothio-
nein has been shown to correlate with chemo-resistance and
prognosis in patients with oesophageal and urothelial cancer (Go
and Adjei, 1999). Similarly, clinical trials have shown that prog-
nosis is related to lung resistance-related protein abnormalities,
which may alter transport of cisplatin; increased repair of cispla-
tin-DNA adducts; and loss of mismatch repair (Fink and Howell,
2000; Giaccone, 2000). Nucleotide excision repair appears to be
the most important pathway for cisplatin-DNA damage, and the
critical gene appears to be excision repair cross-complementing
(ERCC1) (Giaccone, 2000). A number of studies have shown that
high levels of the ERCC1 relative messenger RNA are associated
with response and survival after cisplatin treatment (Giaccone,
2000; Rosell and Felip, 2001). Another genetic abnormality though
to be related to cisplatin resistance affects the apoptosis gene p53;
60% of NSCLC patients have p53 mutations (Giaccone, 2000).
Resistance to carboplatin is less well studied, but it is assumed that
similar mechanisms are involved (Go and Adjei, 1999). The phar-
macogenomics of these agents is therefore being intensively studied
and may dictate therapy choices in the future.
New platinum agents
The problems associated with the use of current platinum agents,
and the need to improve response and survival in patients with
NSCLC (and other cancers), have prompted research into new
platinum agents that have improved toxicity proﬁles, may circum-
vent resistance mechanisms, and have administration schedules
that are acceptable to physicians and patients.
New agents include nedaplatin, a cisplatin-like compound regis-
tered in Japan and active in NSCLC (Judson et al, 1997), and
satraplatin, an orally available drug with dose-limiting toxicity
similar to that of carboplatin currently being explored in prostate
cancer. Two other novel agents, BBR3464 and ZD0473, have shown
good results in preclinical and in vitro studies, and have potential
in the treatment of solid tumours (Judson and Kelland, 2000).
BBR3464 BBR3464 is a trinuclear platinum complex that binds
to DNA more rapidly than cisplatin and forms long-range inter-
strand and intrastrand crosslinks. Phase I studies show diarrhoea
and neutropenia to be dose-limiting toxicities, without signiﬁcant
nephro-, neuro- or pulmonary toxicity (Calvert et al, 1999; Sessa
et al, 2000). Antitumour activity was observed in colorectal and
pancreatic cancer patients after a one-hour infusion of
1.1 mg m
72 every 28 days (Calvert et al, 1999). A second study
(Sessa et al, 2000) showed similar toxicity (0.03–0.17 mg m
72
day
71 for 5 days, repeated every 28 days), in patients with solid
tumours unresponsive to previous antitumour treatment. Phase
II trials are currently underway.
ZD0473 ZD0473 is a new-generation platinum agent designed to
deliver an extended spectrum of antitumour activity and overcome
platinum resistance mechanisms. A common mechanism of resis-
tance is the replacement of the platinum centre by a thiol
moiety. This substitution is hindered by increasing the steric bulk
of the molecule, and ZD0473, with its methyl-substituted pyridine
side chain, was designed with this property in mind (Holford et al,
1998b).
Biochemical studies show that ZD0473 at least partially over-
comes mechanisms of inherent or acquired resistance (Holford et
al, 1998a), and preclinical work indicates activity against cell lines
resistant to older platinum agents (Raynaud et al, 1997). In man,
dose-limiting toxicity is myelosuppression, particularly in patients
previously treated with carboplatin (Trigo et al, 1999; Hoctin-Boes
et al, 2001); without evidence of clinically relevant neurotoxicity,
nephrotoxicity or ototoxicity when given at doses of 120 or
150 mg m
72 (Hoctin-Boes et al, 2001).
Of the newer platinum agents, the new-generation agent ZD0473
could be of interest in NSCLC, with good tolerability having been
reported in phase I trials in which the drug has been given in combi-
nation with paclitaxel, gemcitabine or vinorelbine in patients with
advanced and/or refractory solid tumours (Table 4). These trials
are ongoing, as are phase II monotherapy studies of ﬁrst- and
second-line treatment in patients with NSCLC in which ZD0473
is being given at a dosage of 120–150 mg m
72 every 3 weeks.
CONCLUSIONS
Chemotherapy is now broadly accepted in stage IIIB/IV NSCLC,
and there is growing interest in its use in earlier disease when
Table 4 Phase I studies of ZD0473 in combination with paclitaxel, gemcitabine or vinorelbine in patients with advanced solid tumours
Study Regimens Patients Results reported to date
Douillard et al (2001a) ZD0473 60–120 mg m
72 1–2 h Patients with advanced solid No DLT reported for doses up to
infusion d1+vinorelbine tumours 90/15 mg m
72 ZD0473/vinorelbine
15–30 mg m
72 6–10min
infusion d1 and 8 every 3 weeks
Gatzemeier et al (2001) ZD047360, 90 or 7 NSCLC; 2 mesothelioma Grade 3–4 leucopenia in four patients. No
120 mg m
72 1 h infusion+ 1 SCLC (all refractory DLT. SD in ﬁve out of seven evaluable patients
paclitaxel 135 mg m
72 3 h malignancies) (including two NSCLC with 25%
infusion every 3 weeks reduction in tumour size)
O’Dwyer et al (2001) ZD0473 60–120 mg m
72 1 h 26 with various advanced Grade 3–4 thrombocytopenia or grade 4
infusion d1+gemcitabine solid tumours neutropenia in seven patients. Two MR, both in
600–750 mg m
72 d1 and 8 every 3 weeks patients with gemcitabine- and cisplatin-pretreated
NSCLC; 10 SD. No clinically
relevant nephro- or neurotoxicity
DLT=dose-limiting toxicity; MR=minor response; SD=stable disease; SCLC=small cell lung cancer.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(8), 825–833combined with other (local) therapy. Platinum drugs are still
considered of crucial interest based on clinical studies and the
results of meta-analyses, with the inconvenience of the observed
toxicity and the inherent resistance. These observations have
prompted the development of second generation drugs and
newer platinums (oxaliplatin, BBR3464, ZD0473) and any relative
beneﬁts for these approaches will be investigated in the ongoing
trials.
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